Should I buy or sell Prothena stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRTA shares. View PRTA analyst ratings or view top-rated stocks .

What is Prothena's stock price target for 2024?

9 equities research analysts have issued 1 year price targets for Prothena's stock. Their PRTA share price targets range from $35.00 to $90.00. On average, they predict the company's stock price to reach $69.63 in the next year. This suggests a possible upside of 238.5% from the stock's current price. View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts .

How have PRTA shares performed in 2024?

Prothena's stock was trading at $36.34 at the beginning of 2024. Since then, PRTA shares have decreased by 43.4% and is now trading at $20.57. View the best growth stocks for 2024 here .

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PRTA earnings forecast .

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) posted its earnings results on Thursday, February, 15th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.23) by $0.03. The biotechnology company earned $0.32 million during the quarter, compared to analysts' expectations of $2.15 million. Prothena had a negative net margin of 160.91% and a negative trailing twelve-month return on equity of 24.84%. The firm's quarterly revenue was down 99.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.12 EPS.

What ETFs hold Prothena's stock?

ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , Principal Healthcare Innovators ETF (BTEC) , ALPS Medical Breakthroughs ETF (SBIO) , First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Invesco Nasdaq Biotechnology ETF (IBBQ) . iShares Biotechnology ETF (IBB) .

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA) , Actinium Pharmaceuticals (ATNM) , ArcelorMittal (MT) , Merck & Co., Inc. (MRK) , Energous (WATT) , BioLineRx (BLRX) , Gilead Sciences (GILD) , Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD) .

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PRTA

Prothena (PRTA) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free PRTA Stock Alerts

$20.57

0.00 (0.00%)

(As of 10:31 AM ET)

Compare

Today's Range: $20.42
▼
$21.00
50-Day Range: $20.57
▼
$30.30
52-Week Range: $20.42
▼
$79.65

Volume: 62,143 shs
Average Volume: 764,528 shs
Market Capitalization: $1.11 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $69.63

Get Prothena alerts:

Prothena MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 238.5% Upside
$69.63 Price Target
Short Interest: Bearish
12.04% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.06
Based on 11 Articles This Week
Insider Trading: Selling Shares
$170,000 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.88) to ($4.33) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.86 out of 5 stars

Medical Sector

383rd out of 918 stocks

Pharmaceutical Preparations Industry

173rd out of 430 stocks

4.4

Analyst's Opinion

Consensus Rating
Prothena has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Prothena has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
12.04% of the outstanding shares of Prothena have been sold short.
Short Interest Ratio / Days to Cover
Prothena has a short interest ratio ("days to cover") of 8.1.
Change versus previous month
Short interest in Prothena has recently increased by 3.52%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Prothena does not currently pay a dividend.
Dividend Growth
Prothena does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRTA.

1.1

News and Social Media Coverage

News Sentiment
Prothena has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Prothena this week, compared to 3 articles on an average week.
Search Interest
Only 4 people have searched for PRTA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prothena insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $170,000.00 in company stock.
Percentage Held by Insiders
28.20% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Prothena are expected to grow in the coming year, from ($4.88) to ($4.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prothena is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prothena is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Prothena has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Prothena Stock (NASDAQ:PRTA)

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

PRTA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRTA Stock News Headlines

April 18, 2024 | americanbankingnews.com

Zacks Research Brokers Increase Earnings Estimates for Prothena Co. plc (NASDAQ:PRTA)

April 18, 2024 | americanbankingnews.com

Prothena (NASDAQ:PRTA) Hits New 12-Month Low at $21.31

April 19, 2024 | American Alternative (Ad)

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

April 17, 2024 | investing.com

Prothena reports potential AL amyloidosis treatment

April 16, 2024 | americanbankingnews.com

Financial Comparison: Prothena (NASDAQ:PRTA) and China Health Industries (OTCMKTS:CHHE)

April 15, 2024 | businesswire.com

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

April 13, 2024 | americanbankingnews.com

Q1 2024 EPS Estimates for Prothena Co. plc Cut by Leerink Partnrs (NASDAQ:PRTA)

April 12, 2024 | americanbankingnews.com

Prothena (NASDAQ:PRTA) Sets New 52-Week Low at $21.91

April 19, 2024 | American Alternative (Ad)

Your Money is Not Safe

April 11, 2024 | americanbankingnews.com

Prothena's (PRTA) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

March 13, 2024 | markets.businessinsider.com

Demystifying Prothena Corp: Insights From 8 Analyst Reviews

March 7, 2024 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)

March 5, 2024 | businesswire.com

Prothena to Participate in Upcoming Healthcare Conferences

March 4, 2024 | finance.yahoo.com

Prothena Appoints David Ford to Newly Created Chief People Officer Position

March 1, 2024 | finance.yahoo.com

Prothena Corporation plc (PRTA)

February 23, 2024 | seekingalpha.com

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

February 21, 2024 | msn.com

Prothena appoints Daniel G. Welch as Chair Designate

February 21, 2024 | businesswire.com

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

February 17, 2024 | finance.yahoo.com

PRTA Mar 2024 105.000 call

February 17, 2024 | finance.yahoo.com

Prothena Full Year 2023 Earnings: Beats Expectations

February 16, 2024 | markets.businessinsider.com

Promising Outlook for Prothena’s Amyloidosis Treatments: Analyst Endorses Buy Rating

February 16, 2024 | finance.yahoo.com

Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense

February 16, 2024 | markets.businessinsider.com

RBC Capital Reaffirms Their Hold Rating on Prothena (PRTA)

February 16, 2024 | markets.businessinsider.com

Decoding 6 Analyst Evaluations For Prothena Corp

February 16, 2024 | finance.yahoo.com

Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript

February 15, 2024 | finance.yahoo.com

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

February 15, 2024 | finance.yahoo.com

Prothena Corp PLC (PRTA) Reports 2023 Financial Results and Provides 2024 Outlook

See More Headlines

Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PRTA
CUSIP: N/A
CIK: 1559053
Web: www.prothena.com
Phone: (531) 236-2500
Fax: 353-1902-3510
Employees: 173
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $69.63
High Stock Price Target: $90.00
Low Stock Price Target: $35.00
Potential Upside/Downside: +238.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-147,030,000.00
Net Margins: -160.91%
Pretax Margin: -175.64%
Return on Equity: -24.84%
Return on Assets: -20.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.24
Quick Ratio: 11.24

Sales & Book Value

Annual Sales: $91.37 million
Price / Sales: 12.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.46 per share
Price / Book: 1.97

Miscellaneous

Outstanding Shares: 53,720,000
Free Float: 38,571,000
Market Cap: $1.11 billion
Optionable: Optionable
Beta: 0.21

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Gene G. Kinney Ph.D. (Age 55)
President, CEO & Director
Comp: $1.03M
Mr. Tran B. Nguyen M.B.A. (Age 50)
CFO & Chief Strategy Officer
Comp: $762.86k
Mr. Brandon S. Smith (Age 49)
Chief Operating Officer
Comp: $756.41k
Ms. Carol D. Karp (Age 71)
Chief Regulatory Officer
Comp: $697.51k
Dr. Hideki Garren M.D. (Age 59)
Ph.D., Chief Medical Officer
Comp: $809.59k
Dr. Wagner M. Zago (Age 51)
Chief Scientific Officer
Comp: $478.79k
Mr. Mark C. Johnson C.F.A.
Vice President of Investor Relations
Mr. Michael J. Malecek (Age 58)
Chief Legal Officer & Company Secretary
Comp: $588.25k
Mr. David A. Ford (Age 54)
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Prothena stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRTA shares.
View PRTA analyst ratings or view top-rated stocks.
What is Prothena's stock price target for 2024?: 9 equities research analysts have issued 1 year price targets for Prothena's stock. Their PRTA share price targets range from $35.00 to $90.00. On average, they predict the company's stock price to reach $69.63 in the next year. This suggests a possible upside of 238.5% from the stock's current price.
View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts.
How have PRTA shares performed in 2024?: Prothena's stock was trading at $36.34 at the beginning of 2024. Since then, PRTA shares have decreased by 43.4% and is now trading at $20.57.
View the best growth stocks for 2024 here.
When is Prothena's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PRTA earnings forecast.

How were Prothena's earnings last quarter?: Prothena Co. plc (NASDAQ:PRTA) posted its earnings results on Thursday, February, 15th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.23) by $0.03. The biotechnology company earned $0.32 million during the quarter, compared to analysts' expectations of $2.15 million. Prothena had a negative net margin of 160.91% and a negative trailing twelve-month return on equity of 24.84%. The firm's quarterly revenue was down 99.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.12 EPS.
What ETFs hold Prothena's stock?: ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Principal Healthcare Innovators ETF (BTEC), ALPS Medical Breakthroughs ETF (SBIO), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Invesco Nasdaq Biotechnology ETF (IBBQ).iShares Biotechnology ETF (IBB).
What other stocks do shareholders of Prothena own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).
How do I buy shares of Prothena?: Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Prothena (PRTA) Stock Price, News & Analysis

Prothena MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Prothena Stock (NASDAQ:PRTA)

PRTA Stock Price History

PRTA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PRTA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™